The DOI matches its Crossref record.
Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: Evidence for a role of hepatocyte growth factor
Open accessAbstract
The stroma of hepatocellular carcinomas (HCC) is infiltrated with myofibroblasts (MFs). Preliminary in vivo data have suggested that liver MF express hepatocyte growth factor (HGF), a cytokine that has been implicated in several tumor models. Our aim was to investigate the role of MF and HGF in HCC. Cultured liver MF expressed HGF messenger RNA (mRNA) and secreted HGF in their medium, as shown by Western blot, immunoprecipitation, and enzyme-linked immunosorbent assay (ELISA). Addition of MF-conditioned medium to the HepG2 HCC cell line induced cell scattering. This was associated with a decrease in cell proliferation. MF also increased about 100-fold the ability of HepG2 to invade Matrigel. Increased invasiveness was also shown for HuH7 cells, but no scattering was observed and cell proliferation was stimulated. All the effects of MF on both tumor cell types were blocked by addition of an antibody to HGF and they all could be reproduced by adding recombinant HGF to the tumor cells. RT-PCR and Western blot analysis confirmed that both tumor cell lines expressed c-met, the receptor for HGF. The effects of MF-conditioned medium were not reproduced by acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor (EGF), transforming growth factor-β1 (TGF-β1), or platelet-derived growth factor (PDGF-BB). Reverse transcription-polymerase chain reaction (RT-PCR) analysis confirmed that HGF was expressed in human HCC. Our data show that human liver MF act on HCC cells to increase their invasiveness and suggest that MF-derived HGF could be involved in the pathogenesis of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042
“Myofibroblasts have been observed in cancer of the colon [92], the breast [93], the liver [94], the lung [95], the prostate [96], and the pancreas [97]; they were located mainly at the invasion front.”
BackgroundThe Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
“Neutralization of HSC-secreted HGF inhibits the proliferation and invasion capacity of HepG2, Huh7, Hep3b, and PLC cells in vitro (83, 160).”
BackgroundRole of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
The stroma reaction myofibroblast: a key player in the control of tumor cell behavior
Desmouliere, A., Guyot, C., & Gabbiani, G. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041802ad · Cited by 551
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 485
De Wever, O., Nguyen, Q., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., & Mareel, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1110fje · Cited by 402
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 391
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Ohuchida, K., Mizumoto, K., Murakami, M., Qian, L.-W., Sato, N., Nagai, E., Matsumoto, K., Nakamura, T., & Tanaka, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2464 · Cited by 384
Desmoulière, A., Darby, I. A., & Gabbiani, G. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000101911.53973.90 · Cited by 363
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Dietary Antioxidant Compounds and Liver Health
Vitaglione, P., Morisco, F., Caporaso, N., & Fogliano, V. (2004) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690490911701 · Cited by 305
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma
Amann, T., Bataille, F., Spruss, T., Mühlbauer, M., Gäbele, E., Schölmerich, J., Kiefer, P., Bosserhoff, A., & Hellerbrand, C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01087.x · Cited by 277
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
“Third, CAFs promote angiogenesis by producing angiogenic factors such as VEGF and HGF. 21,72,73 76 The CAF induction mechanism is not fully understood in HCC but has been proposed in other cancers (e.g., melanoma and breast cancer).”
Wang, X.-Y., Pei, Y., Xie, M., Jin, Z.-H., Xiao, Y.-S., Wang, Y., Zhang, L.-N., Li, Y., & Huang, W.-H. (2015) · Lab on a Chip · doi:10.1039/c4lc00973h · Cited by 77
Morisco, F., Vitaglione, P., Amoruso, D., Russo, B., Fogliano, V., & Caporaso, N. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.09.003 · Cited by 67
Metadata
- Authors
- Neaud, V, Faouzi, S., Guirouilh, J., Le Bail, B., Balabaud, C., Bioulac-Sage, P., & Rosenbaum, J.
- Venue
- Hepatology
- Published
- 1997-12
- Volume
- 26
- Issue
- 6
- Pages
- 1458-1466
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4234752386
- Cited by
- 167
- References
- 0
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.